Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
British Journal of Clinical Pharmacology|July 31, 2023
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimenSara Bettonte, Mattia Berton, Felix Stader, et al.
Open Forum Infectious Diseases|July 27, 2023
Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong InducersMattia Berton, Sara Bettonte, Felix Stader, et al.
Clinical Pharmacokinetics|December 26, 2022
Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese IndividualsMattia Berton, Sara Bettonte, Felix Stader, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 6, 2023
Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 SubstratesSara Bettonte, Mattia Berton, Felix Stader, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 17, 2026
Evaluating alterations in drug-metabolizing enzymes in cancer: insights from in vivo, in vitro, and biomarker studiesEman El-Khateeb, Oliver Hatley, Iain Gardner, et al.
Clinical Pharmacology and Therapeutics|February 1, 2021
Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIVFelix Stader, Perrine Courlet, Laurent A Decosterd, et al.
The AAPS Journal|November 6, 2025
Utilizing Minimal Physiologically Based Pharmacokinetic Modeling to Bridge Bevacizumab Pharmacokinetics from Adult to Pediatric PatientsOlagoke Sule, Felix Stader, Nastya Kassir, et al.
Pharmaceutics|July 30, 2025
Mechanistic Insights into Cytokine Antagonist-Drug Interactions: A Physiologically Based Pharmacokinetic Modelling Approach with Tocilizumab as a Case StudyXian Pan, Cong Liu, Felix Stader, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 10, 2025
Modeling and Simulation Identifies Endocytosis Uptake Rate and Fraction Unbound as Important Predictors of Oligonucleotide PharmacokineticsFelix Stader, Abdallah Derbalah, Adriana Zyla, et al.
Pharmaceutics|October 26, 2024
Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK FrameworkAneesh V Karkhanis, Matthew D Harwood, Felix Stader, et al.
Pageof 5